Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Abnormal results led to individualized letter to PCP ▪ Follow-up patient phone calls: 4, 8 and 12 months ▪ Safety net: if patients untreated at 4 and/or 8 months, intervention letter sent to PCP to advise treatmentControl group (n = 200): ▪ Follow-up patient phone calls: 6 and 12 months (without mention of osteoporosis)Safety net: if patients untreated at 12 months, verbal education provided and intensive intervention offeredRate of osteoporosis treatment at 12 months:▪ Change in treatment rate from baseline rate: + 31.6% in minimum group (p < 0.001 vs. control), + 42.6% in intensive group (p < 0.0001 vs. control), + 16.1% in control group▪ Among those initially untreated at baseline: 40.4% in minimum group (p < 0.0001 vs. control), 53.2% in intensive group (p < 0.0001 vs. control), 18.8% in control groupConfirmation with patient’s pharmacistJaglal et al. 2012 (Canada)Patients ≥ 40 years with fracture of hip, forearm, wrist, rib, sternum, thoracic and lumbar spine, shoulder and upper arm, pelvis, lower leg and ankleFracture not due to fall from standing height, nursing home residents, or fractures occurring > 3 months agoIntervention group (n = 130): ▪ Patient education (verbal and written): osteoporosis information, importance of PCP follow-up and need for BMD test ▪ Letter to PCP: patient’s FF, rationale for osteoporosis treatment, pocket cards for osteoporosis screening and treatment ▪ Follow-up patient phone calls: 3 monthsControl group (n = 137): Patient education (verbal and written): falls preventionRate of osteoporosis treatment at 6 months OR if normal BMD, prevention advice given:▪ 45% in intervention group vs. 26% in control group (p = 0.003)Rate of BMD test scheduled or performed at 6 months:▪ 57% in intervention group vs. 21% in control group (p = < 0.0001)Interview with patientCranney et al. 2008 (Canada)Postmenopausal women with wrist fractureTraumatic fracture, current osteoporosis treatment except hormone replacement therapyIntervention group (n = 125): ▪ Patient education (written): letter sent 2 weeks and 2 months after fracture, checklist of risk factors to calculate risk score, osteoporosis information and importance of PCP follow-up ▪ Letter to PCP: letter sent 2 weeks and 2 months after fracture, patient’s FF, rationale for osteoporosis treatment, treatment algorithmControl group (n = 145): No additional communication1Rate of osteoporosis treatment at 6 months:▪ 28% in intervention group vs. 10% in control group (p = 0.002)Rate of BMD test performed at 6 months:▪ 53.5% in intervention group vs. 25.5% in control group (p < 0.0001)Interview with patientBessette et al. 2011 (Canada)Women ≥ 50 years with FF of wrist, forearm, humerus, scapula, clavicle, sternum, thoracic or lumbar vertebrae, pelvis, sacrum, hip, femur, proximal and distal tibia, fibula and footCervical spine, skull or face, hand or finger, toe, foot or patella, pathological fractures, nursing home residents, participation in another osteoporosis trialWritten material group (n = 379): ▪ Patient education (written): osteoporosis information, importance of PCP follow-up and need for BMD test ▪ Letter to PCP: rationale for osteoporosis treatmentVideo and written material group (n = 409): ▪ Patient education (15 min video): osteoporosis information, importance of PCP follow-up and need for BMD test, non-pharmacological therapies, falls prevention ▪ Patient education (written): osteoporosis information, importance of PCP follow-up and need for BMD test ▪ Letter to PCP: rationale for osteoporosis treatmentControl group (n = 386): No additional communicationRate of osteoporosis treatment at 12 months:▪ 11% in video and written material group (p = 0.06 vs. control), 12% in written material group (p = 0.05 vs. control) and 8% in control groupRate of BMD test performed at 12 months▪ 16% in video and written material group (p = 0.04 vs. control), 15% in written material group (p = 0.07 vs. control) and 12% in control groupInterview with patientLeslie et al. 2012 (Canada)Patients ≥ 50 years with fracture of hip, spine, humerus or forearmCurrent osteoporosis treatment, previous fracture within 12 months of recent fracture, BMD test within 3 years of recent fracture, nursing home residentsPhysician and patient notification intervention group (n = 1421): ▪ Patient education (written): osteoporosis information, importance of PCP follow-up ▪ Letter to PCP: patient’s FF, rationale for osteoporosis treatment, BMD request formPhysician notification intervention group (n = 1363): ▪ Letter to PCP: patient’s FF, rationale for osteoporosis treatment, BMD request formControl group (n = 1480): No additional communicationRate of osteoporosis treatment at 12 months:▪ 16.5% in physician and patient group, 14.7% in physician group, 10.6% in control group (p values not available)Rate of BMD test performed at 12 months:▪ 18.2% in physician and patient group, 16.4% in physician group, 3.9% in control group (p values not available)Data linkage with healthcare databaseMajumdar et al. 2004 (Canada)Patients ≥ 50 years with wrist fractureCurrent osteoporosis treatment, admitted patients, nursing home residentsIntervention group (n = 55): ▪ Patient education (written): osteoporosis information ▪ Patient education (verbal): osteoporosis information, importance of PCP follow-up ▪ Letter to PCP: patient’s FF, rationale for osteoporosis treatmentControl group (n = 47): ▪ Letter to PCP: patient’s fracture (without mention of osteoporosis) and clinic follow-up plansPatient education (verbal and written): falls preventionRate of osteoporosis treatment at 6 months:▪ 40% in intervention group vs. 10% in control group (p = 0.002)Rate of BMD test performed at 6 months:▪ 62% in intervention group vs. 17% in control group (p < 0.001)Interview with patient and confirmation with patient’s pharmacistMajumdar et al. 2007 (Canada)Patients ≥ 50 years undergoing hip fracture surgeryCurrent osteoporosis treatment, nursing home residents, pathological fracturesIntervention group (n = 110): ▪ Patient education (written): osteoporosis information, importance of PCP follow-up ▪ Patient education (verbal): importance of BMD testing ▪ Arrangement of BMD test and result review ▪ Prescription of oral bisphosphonate if low BMDControl group (n = 110): ▪ Patient education (written): osteoporosis information, importance of PCP follow-up ▪ Patient education (verbal): falls prevention, importance of calcium and Vitamin D intakeRate of osteoporosis treatment at 6 months (post-intervention):▪ 54% in intervention group (p < 0.001 vs. control), 38% in facilitated intervention group (p < 0.001 vs. control), 22% in control groupRate of BMD test performed at 6 months (post-intervention):▪ 80% in intervention group (p < 0.001 vs. control), 68% in facilitated intervention group (p < 0.001 vs. control), 29% in control groupRate of appropriate care (BMD performed and treatment started in those with low BMD) at 6 months (post-intervention):▪ 71% in intervention group (p < 0.001 vs. control), 45% in facilitated intervention group (p < 0.001 vs. control), 26% in control groupInterview with patientMorrish et al. 2009 (Canada)Second phase of above studyIn second phase of the study (6 months post initial intervention), the control group was enrolled in facilitated intervention group (n = 110): ▪ Arrangement of BMD testing Letter to PCP with BMD test resultHawker et al. 2003 (Canada)Patients ≥ 40 years with fracture of wrist, hip, ankle, vertebrae or humerusTraumatic fracture, current osteoporosis treatmentIntervention group (n = 139): ▪ Patient education (verbal): osteoporosis information, importance of PCP follow-up ▪ Letter to PCP (given to patient, not PCP): patient’s FF, rationale for osteoporosis treatmentControl group (n = 139): No additional communicationRate of any treatment at 3 months for intervention, 3 to 9 months for controls:▪ 24.4% in intervention group vs. 31.4% in control group (OR 1.04, CI 0.53 to 2.03)Rate of BMD test performed at 3 months for intervention, 3 to 9 months for controls:▪ 81.7% in intervention group vs. 92% in control group (OR 0.26, CI 0.14 to 0.51)Interview with patientGardner et al. 2005 (USA)Patients ≥ 65 years admitted with hip fractureCurrent osteoporosis treatment, traumatic fracture, history of alcoholism or dementiaIntervention group (n = 36): ▪ Patient education (verbal): 15 min face-to-face, osteoporosis information, importance of PCP follow-up, question list for PCP ▪ Follow-up patient phone calls: 6 weeksControl group (n = 36): Patient education (written): falls prevention with brief mention of osteoporosisRate of osteoporosis ‘being addressed’ at 6 months:▪ 42% in intervention group vs. 19% in control group (p = 0.036)Interview with patientRozental et al. 2008 (USA)Women ≥ 50 years and men ≥ 65 years with radius fractureCurrent osteoporosis treatment, BMD test within 2 years of recent fracture, traumatic fractureIntervention group 1 (n = 27): ▪ Arrangement of BMD testing ▪ Letter to PCP: BMD test resultIntervention group 2 (n = 23): ▪ Letter to PCP: patient’s FF, rationale for osteoporosis treatment No control groupRate of osteoporosis treatment at 6 months:▪ 74% in intervention group 1 vs. 26% in intervention group 2 (p < 0.001)Rate of BMD test performed at 6 months:▪ 93% in intervention group 1 vs. 30% in intervention group 2 (p < 0.001)Interview with patient and review of medical recordsSkedros, 2004 (USA)Patients ≥ 50 years with FFCurrent osteoporosis treatment, nursing home residents, cognitive impairment, requiring support devicesIntervention group (n = 69) ▪ Patient education (verbal): osteoporosis information, importance of PCP follow-up ▪ Letter to PCP: patient’s FF, rationale for osteoporosis treatment No control groupRate of PCP follow-up at 3 months: 56.5%Rate of osteoporosis treatment (out of those who followed up) at 3 months: 56.4%Rate of BMD test performed (out of those who followed up) at 3 months: 43.6%Method of outcome assessment not specifiedFeldstein et al. 2006 (USA)Women aged 50 to 89 years with FFFractures of skull, face, fingers, toes, ankle or open fracture suggestive of trauma, current osteoporosis treatment, previous BMD test, nursing home residents, malignancy, chronic renal failure, dementia, organ transplant, cirrhosis, participation in another osteoporosis trialEMR and patient notification intervention group (n = 113): ▪ Patient education (written): osteoporosis information, importance of PCP follow-up ▪ EMR notification to PCP: patient’s FF, rationale for osteoporosis treatment, treatment guidelines ▪ Follow-up EMR reminder: 3 months if no treatment or BMD test is orderedEMR notification intervention group (n = 107): ▪ EMR notification to PCP: patient’s FF, rationale for osteoporosis treatment, treatment guidelines ▪ Follow-up EMR reminder: 3 months if no treatment or BMD test is orderedControl group (n = 107): No additional communicationRate of osteoporosis treatment or BMD test performed at 6 months:▪ 43.1% in EMR and patient intervention group (p < 0.001 vs. control), 51.5% in EMR intervention group (p < 0.001 vs. control, 5.9% in controlData linkage with healthcare databaseWood et al. 2017 (UK)Patients admitted with neck of femur fracturePre-intervention group (n = 22): ▪ Patient reviewed as suitable for denosumab while inpatient ▪ No standardized wording of denosumab recommendation for PCP on discharge summaryIntervention group (n = 30): ▪ Patient reviewed as suitable for denosumab while inpatient ▪ Documentation of ‘denosumab: GP to prescribe and start on discharge’ on hospital notes intended to be included in discharge summaryLetter to PCP: recommendation for denosumabRate of denosumab treatment (no clear timeframe):▪ 22% in pre-intervention group vs. 74% in post-intervention groupConfirmation with patient’s PCPNaranjo et al. 2014 (Spain)Patients ≥ 50 years with FFFractures of face, skull, ribs, hands, feet, pathological fracture, severe functional disability, advanced liver disease, renal failure, serious medical illnessIntervention group (n = 330): ▪ Patient education (verbal): face-to-face, osteoporosis information, importance of PCP follow-up, bisphosphonate education ▪ Prescription of oral bisphosphonate based on criteria ▪ Arrangement of BMD testing ▪ Letter to PCP: BMD test result ▪ PCP education: rheumatologist-led 60 min session, explanation of study, rationale for osteoporosis treatmentNo control groupRate of bisphosphonate continuation in those prescribed bisphosphonate at 3 months: 78%Interview with patient and review of medical recordsSanfelix-Genoves et al. 2010 (Spain)Patients ≥ 50 years receiving healthcare as part of longitudinal observational prospective cohort study (ESOSVAL-R)Intervention group (n = 400 general practices): ▪ EMR improvement: new follow-up sheet, risk factor variables for osteoporosis patients ▪ PCP education: 4 h classroom session, online educationControl group (n = 400 general practices): EMR improvement: new follow-up sheet, risk factor variables for osteoporosis patientsRate of ‘appropriate treatment’ according to established national and international osteoporosis guidelinesRate of patients ≥ 70 years diagnosed with osteoporosis and/or FF with osteoporosis treatment compared to all people ≥ 70 years in the practice▪ Follow-up ongoingData linkage with healthcare databaseKessous et al. 2014 (Israel)Women aged 48 to 70 years with radius fractureCurrent treatment for or previous diagnosis of osteoporosis, tumour-related pathological fractures, chronic steroid useIntervention group (n = 35): ▪ Patient education (written): osteoporosis information ▪ Patient education (verbal): questionnaire about osteoporosis knowledge (also in control group) ▪ Letter to PCP: rationale for osteoporosis treatmentControl group (n = 35): Baseline questionnaire which asked about osteoporosis knowledge and prior workup and mentioned possible link between FF and osteoporosisRate of referral to PCP at 6 to 8 weeks:68.6% in intervention group vs. 22.9% in control group (p = 0.001)Rate of BMD test performed at 6 to 8 weeks:40% in intervention group vs. 14.3% in control group (p = 0.001)Interview with patientGoldshtein et al. 2020 (Israel)Patients with either recorded T-score ≤ − 2.5 SD (primary prevention subgroup) or femoral neck or clinical vertebral fracture (secondary prevention subgroup)Current osteoporosis treatment, traumatic fracturePre-intervention group (unclear number): ▪ No physician alert notificationIntervention group (n = 21,070): ▪ EMR alert to PCP, endocrinologist or geriatrician: EMR pop-up alert with ‘smart-set’ screens to order blood tests, order prescriptions for osteoporosis treatment, refer to specialists or allied health, print information page for patientTime from event until initiation of osteoporosis treatment:Time to treatment initiation shorter in post-intervention group than pre-intervention group for secondary prevention subgroup (p < 0.001)Rate of osteoporosis treatment at 6 months:Post-intervention 27.7% vs. pre-intervention 12.3% for hip fracture subgroup (p < 0.001)Post-intervention 27.1% vs. pre-intervention 17.4% for vertebral fracture subgroup (p < 0.001)Data linkage with healthcare databaseBliuc et al. 2006 (Australia)Patients ≥ 20 years with FFCurrent osteoporosis treatment, traumatic fracture, finger or toe fracturesLetter and BMD test group (n = 79): ▪ Patient education (written): osteoporosis information, importance of PCP follow-up ▪ Offer of BMD test with results sent back to patient to bring to PCPLetter group (n = 75): ▪ Patient education (written): osteoporosis information, importance of PCP follow-upRate of osteoporosis treatment at 6 months:Letter and BMD test group 5% vs. letter group 7% (no diff.)Rate of BMD test performed at 6 months:Letter and BMD test group 38% vs. letter group 7% (p = 0.001)Interview with patientWang et al. (in progress) (Australia)Patients ≥ 50 years referred for a scan by their PCP to a private radiology practice) or a hospital-based FLS with a FF diagnosed by natural language processing technologyTraumatic or pathological fracture, complex or major fractures (FLS only), fractures of toes, fingers, face, ankle (women only), current osteoporosis treatment, pregnant womenIntervention group (n = 600): ▪ Alert to PCP: electronic and/or fax alert informing PCP of recent FF, rationale for osteoporosis treatment, osteoporosis guidelines, post-treatment surveys, reminder alertsControl group (n = 600): ▪ No additional communicationRate of osteoporosis treatment at 3 monthsRate of BMD test performed at 3 monthsRate of chronic disease management plan initiation at 3 monthsRate of osteoporosis-related blood test at 3 monthsRate of continued prescription of osteoporosis treatment at 9 monthsData linkage with healthcare database1No additional communication refers to no additional osteoporosis-directed intervention.
Source: Quantitative studies. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Narrative review.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Secondary fracture prevention in primary care: a narrative review
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Secondary fracture prevention in primary care: a narrative review
Narrative review · Osteoporosis International · 2024
Original publication title
Secondary fracture prevention in primary care: a narrative review
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
The global burden of osteoporosis continues to rise with an ageing population. Untreated osteoporotic fractures not only heighten the risk of subsequent fractures but are associated with excess mortality. Although primary care guidelines consistently stress the importance of secondary fracture prevention, fewer than 20% of patients are appropriately treated for osteoporosis following an initial osteoporotic fracture. This worldwide phenomenon is known as the osteoporosis care gap. This literature review examines the barriers to secondary fracture prevention in primary care and evaluates the effectiveness of targeted primary care interventions.
Common themes emerged from the majority of qualitative studies, including a need for improved communication between the hospital team and primary care, better defined responsibilities and osteoporosis-directed education for the primary care physicians. Quantitative studies demonstrated that most targeted, intensive interventions aimed at educating patients and their primary care physician about osteoporosis treatment significantly increased rates of investigation and treatment. Greater uptake of models of secondary fracture prevention in primary care is urgently needed to address the osteoporosis care gap.
Authors’ abstract
The global burden of osteoporosis continues to rise with an ageing population. Untreated osteoporotic fractures not only heighten the risk of subsequent fractures but are associated with excess mortality. Although primary care guidelines consistently stress the importance of secondary fracture prevention, fewer than 20% of patients are appropriately treated for osteoporosis following an initial osteoporotic fracture. This worldwide phenomenon is known as the osteoporosis care gap. This literature review examines the barriers to secondary fracture prevention in primary care and evaluates the effectiveness of targeted primary care interventions.
Common themes emerged from the majority of qualitative studies, including a need for improved communication between the hospital team and primary care, better defined responsibilities and osteoporosis-directed education for the primary care physicians. Quantitative studies demonstrated that most targeted, intensive interventions aimed at educating patients and their primary care physician about osteoporosis treatment significantly increased rates of investigation and treatment. Greater uptake of models of secondary fracture prevention in primary care is urgently needed to address the osteoporosis care gap.
Publication and source details
Original title: Secondary fracture prevention in primary care: a narrative review
Mawson Wang; Markus J. Seibel
Osteoporosis International · 2024
© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.NHMRCAPP 1196062Seibel Markus J. University of SydneyOpen Access funding enabled and organized by CAUL and its Member Institutions
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T12:00:39.707129+00:00
DOI: 10.1007/s00198-024-07036-1 · PMC11281980